Theriva Biologics (TOVX) Cash from Investing Activities (2010 - 2025)
Theriva Biologics (TOVX) posted quarterly Cash from Investing Activities of -$19000.0 for Q3 2025, up 66.07% quarter-over-quarter from -$56000.0 in Q4 2023.
Theriva Biologics (TOVX) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Theriva Biologics (TOVX) has reported Cash from Investing Activities for 14 consecutive years, with -$19000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Investing Activities changed N/A year-over-year to -$19000.0; the TTM figure through Dec 2025 stood at -$19000.0 (up 89.73% YoY), while the FY2025 annual figure was -$35000.0, down 3400.0% from the prior year.
- Cash from Investing Activities grew to -$19000.0 in Q3 2025 per TOVX's latest filing, from -$56000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$8000.0 in Q1 2023 and bottomed at -$4.3 million in Q1 2022.
- Historically, Cash from Investing Activities has averaged -$463100.0 across 4 years, with a median of -$16500.0 in 2021.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 30471.43% — and 2023, when it surged 99.81%.
- Theriva Biologics' Cash from Investing Activities stood at -$14000.0 in 2021, then sank by 550.0% to -$91000.0 in 2022, then surged by 38.46% to -$56000.0 in 2023, then soared by 66.07% to -$19000.0 in 2025.
- Business Quant data shows TOVX's Cash from Investing Activities at -$19000.0 in Q3 2025, -$56000.0 in Q4 2023, and -$129000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -19,000.00 |
| Sep 30, 2025 | -19,000.00 |
| Dec 31, 2023 | -56,000.00 |
| Dec 31, 2023 | -56,000.00 |
| Sep 30, 2023 | -129,000.00 |
| Sep 30, 2023 | -129,000.00 |
| Jun 30, 2023 | -9,000.00 |
| Jun 30, 2023 | -9,000.00 |
| Mar 31, 2023 | -8,000.00 |
| Mar 31, 2023 | -8,000.00 |
| Dec 31, 2022 | -91,000.00 |
| Dec 31, 2022 | -91,000.00 |
| Sep 30, 2022 | -11,000.00 |
| Sep 30, 2022 | -11,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | -4.28 Mn |
| Mar 31, 2022 | -4.28 Mn |
| Mar 31, 2021 | -14,000.00 |
| Mar 31, 2021 | -14,000.00 |